Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 259

1.

Implementation of an advance directive focus in a Chronic Multi-Organ Rare Disease Clinic.

Elorreaga N, Allred D, Ortiz G, McNeill C, Scholand MB, Frech TM.

Ann Palliat Med. 2017 Dec;6(Suppl 2):S206-S208. doi: 10.21037/apm.2017.08.06. Epub 2017 Aug 31.

2.

Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition.

Gil Del Alcazar CR, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F, Zi X, Kwak M, Bergholtz H, Su Y, Ding L, Russnes HG, Richardson AL, Babski K, Min Hui Kim E, McDonnell CH 3rd, Wagner J, Rowberry R, Freeman GJ, Dillon D, Sorlie T, Coussens LM, Garber JE, Fan R, Bobolis K, Allred DC, Jeong J, Park SY, Michor F, Polyak K.

Cancer Discov. 2017 Oct;7(10):1098-1115. doi: 10.1158/2159-8290.CD-17-0222. Epub 2017 Jun 26.

PMID:
28652380
3.

Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer.

Goncalves R, DeSchryver K, Ma C, Tao Y, Hoog J, Cheang M, Crouch E, Dahiya N, Sanati S, Barnes M, Sarian LOZ, Olson J, Allred DC, Ellis MJ.

Breast Cancer Res Treat. 2017 Sep;165(2):355-364. doi: 10.1007/s10549-017-4329-y. Epub 2017 Jun 13.

4.

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).

Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, DeSchryver K, Crouch E, Brink A, Watson M, Luo J, Tao Y, Barnes M, Dowsett M, Budd GT, Winer E, Silverman P, Esserman L, Carey L, Ma CX, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther JM, Dayao Z, Ota D, Leitch M, Olson JA Jr, Allred DC, Hunt K.

J Clin Oncol. 2017 Apr 1;35(10):1061-1069. doi: 10.1200/JCO.2016.69.4406. Epub 2017 Jan 3.

5.

An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors.

Luo J, Liu S, Leung S, Gru AA, Tao Y, Hoog J, Ho J, Davies SR, Allred DC, Salavaggione AL, Snider J, Mardis ER, Nielsen TO, Ellis MJ.

J Mol Diagn. 2017 Jan;19(1):147-161. doi: 10.1016/j.jmoldx.2016.09.007.

6.

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients.

Kurozumi S, Padilla M, Kurosumi M, Matsumoto H, Inoue K, Horiguchi J, Takeyoshi I, Oyama T, Ranger-Moore J, Allred DC, Dennis E, Nitta H.

Breast Cancer Res Treat. 2016 Jul;158(1):99-111. doi: 10.1007/s10549-016-3856-2. Epub 2016 Jun 18.

7.

Extensive Shared Chemosensitivity between Malaria and Babesiosis Blood-Stage Parasites.

Paul AS, Moreira CK, Elsworth B, Allred DR, Duraisingh MT.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):5059-63. doi: 10.1128/AAC.00928-16. Print 2016 Aug.

8.

Shared elements of host-targeting pathways among apicomplexan parasites of differing lifestyles.

Pellé KG, Jiang RH, Mantel PY, Xiao YP, Hjelmqvist D, Gallego-Lopez GM, O T Lau A, Kang BH, Allred DR, Marti M.

Cell Microbiol. 2015 Nov;17(11):1618-39. doi: 10.1111/cmi.12460. Epub 2015 Jul 7.

PMID:
25996544
9.

Rehabilitation of moderate-to-severe traumatic brain injury.

Eapen BC, Allred DB, O'Rourke J, Cifu DX.

Semin Neurol. 2015 Feb;35(1):e1-3. doi: 10.1055/s-0035-1549094. Epub 2015 Mar 27. Review.

PMID:
25816124
10.

Timing of adjuvant surgical oophorectomy in the menstrual cycle and disease-free and overall survival in premenopausal women with operable breast cancer.

Love RR, Laudico AV, Van Dinh N, Allred DC, Uy GB, Quang le H, Salvador JD, Siguan SS, Mirasol-Lumague MR, Tung ND, Benjaafar N, Navarro NS Jr, Quy TT, De La Peña AS, Dofitas RB, Bisquera OC Jr, Linh ND, To TV, Young GS, Hade EM, Jarjoura D.

J Natl Cancer Inst. 2015 Mar 19;107(6):djv064. doi: 10.1093/jnci/djv064. Print 2015 Jun.

11.

Caregiver burden and sibling relationships in families raising children with disabilities and typically developing children.

Roper SO, Allred DW, Mandleco B, Freeborn D, Dyches T.

Fam Syst Health. 2014 Jun;32(2):241-6. doi: 10.1037/fsh0000047. Epub 2014 May 12.

PMID:
24818514
12.

The evolutionary dynamics of variant antigen genes in Babesia reveal a history of genomic innovation underlying host-parasite interaction.

Jackson AP, Otto TD, Darby A, Ramaprasad A, Xia D, Echaide IE, Farber M, Gahlot S, Gamble J, Gupta D, Gupta Y, Jackson L, Malandrin L, Malas TB, Moussa E, Nair M, Reid AJ, Sanders M, Sharma J, Tracey A, Quail MA, Weir W, Wastling JM, Hall N, Willadsen P, Lingelbach K, Shiels B, Tait A, Berriman M, Allred DR, Pain A.

Nucleic Acids Res. 2014 Jun;42(11):7113-31. doi: 10.1093/nar/gku322. Epub 2014 May 5.

13.

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF; American Society of Clinical Oncology; College of American Pathologists.

J Clin Oncol. 2013 Nov 1;31(31):3997-4013. doi: 10.1200/JCO.2013.50.9984. Epub 2013 Oct 7.

PMID:
24101045
14.

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF; American Society of Clinical Oncology; College of American Pathologists.

Arch Pathol Lab Med. 2014 Feb;138(2):241-56. doi: 10.5858/arpa.2013-0953-SA. Epub 2013 Oct 7.

15.

Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα(+) tumorigenesis.

Chan SR, Rickert CG, Vermi W, Sheehan KC, Arthur C, Allen JA, White JM, Archambault J, Lonardi S, McDevitt TM, Bhattacharya D, Lorenzi MV, Allred DC, Schreiber RD.

Cell Death Differ. 2014 Feb;21(2):234-46. doi: 10.1038/cdd.2013.116. Epub 2013 Sep 13.

16.

Loss of Par3 promotes breast cancer metastasis by compromising cell-cell cohesion.

Xue B, Krishnamurthy K, Allred DC, Muthuswamy SK.

Nat Cell Biol. 2013 Feb;15(2):189-200. doi: 10.1038/ncb2663. Epub 2012 Dec 23.

17.

Unusual chromatin structure associated with monoparalogous transcription of the Babesia bovis ves multigene family.

Huang Y, Xiao YP, Allred DR.

Int J Parasitol. 2013 Feb;43(2):163-72. doi: 10.1016/j.ijpara.2012.10.018. Epub 2012 Nov 23.

18.

FGFR1 amplification and the progression of non-invasive to invasive breast cancer.

Gru AA, Allred DC.

Breast Cancer Res. 2012 Nov 14;14(6):116. doi: 10.1186/bcr3340.

19.

Characterization of chemical speciation in ultrathin uranium oxide layered films.

He H, Wang P, Allred DD, Majewski J, Wilkerson MP, Rector KD.

Anal Chem. 2012 Dec 4;84(23):10380-7. doi: 10.1021/ac302598r. Epub 2012 Nov 15.

PMID:
23131069
20.

Pathologic outcomes of nonmalignant papillary breast lesions diagnosed at imaging-guided core needle biopsy.

Holley SO, Appleton CM, Farria DM, Reichert VC, Warrick J, Allred DC, Monsees BS.

Radiology. 2012 Nov;265(2):379-84. doi: 10.1148/radiol.12111926. Epub 2012 Sep 5.

PMID:
22952379
21.

Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Soliman H, Somlo G, Theriault RL, Ward JH, Wolff AC, Zellars R, Kumar R, Shead DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Jul 1;10(7):821-9.

22.

Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer.

Lee S, Stewart S, Nagtegaal I, Luo J, Wu Y, Colditz G, Medina D, Allred DC.

Cancer Res. 2012 Sep 1;72(17):4574-86. doi: 10.1158/0008-5472.CAN-12-0636. Epub 2012 Jul 2.

23.

Whole-genome analysis informs breast cancer response to aromatase inhibition.

Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER.

Nature. 2012 Jun 10;486(7403):353-60. doi: 10.1038/nature11143.

24.

Intra-mammary ductal transplantation: a tool to study premalignant progression.

Medina D, Edwards DG, Kittrell F, Lee S, Allred DC.

J Mammary Gland Biol Neoplasia. 2012 Jun;17(2):131-3. doi: 10.1007/s10911-012-9259-z. Epub 2012 Jun 12. Review.

PMID:
22688217
25.

Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.

Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, Mamounas EP, Julian TB, Geyer CE Jr, Costantino JP, Land SR, Wolmark N.

J Clin Oncol. 2012 Apr 20;30(12):1268-73. doi: 10.1200/JCO.2010.34.0141. Epub 2012 Mar 5.

26.

Outbreak of equine piroplasmosis in Florida.

Short MA, Clark CK, Harvey JW, Wenzlow N, Hawkins IK, Allred DR, Knowles DP, Corn JL, Grause JF, Hennager SG, Kitchen DL, Traub-Dargatz JL.

J Am Vet Med Assoc. 2012 Mar 1;240(5):588-95. doi: 10.2460/javma.240.5.588.

PMID:
22332629
27.

Characterization of the unusual bidirectional ves promoters driving VESA1 expression and associated with antigenic variation in Babesia bovis.

Wang X, Xiao YP, Bouchut A, Al-Khedery B, Wang H, Allred DR.

Eukaryot Cell. 2012 Mar;11(3):260-9. doi: 10.1128/EC.05318-11. Epub 2012 Jan 27.

28.

Molecular biomarkers of risk in premalignancy and breast cancer prevention.

Allred DC.

Cancer Prev Res (Phila). 2011 Dec;4(12):1947-52. doi: 10.1158/1940-6207.CAPR-11-0478.

29.

Human primary ductal carcinoma in situ (DCIS) subtype-specific pathology is preserved in a mouse intraductal (MIND) xenograft model.

Valdez KE, Fan F, Smith W, Allred DC, Medina D, Behbod F.

J Pathol. 2011 Dec;225(4):565-73. doi: 10.1002/path.2969. Epub 2011 Sep 26.

30.

Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.

Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC, Esserman LJ, Unzeitig GW, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Watson MA, Leitch M, Hunt K, Olson JA.

J Clin Oncol. 2011 Jun 10;29(17):2342-9. doi: 10.1200/JCO.2010.31.6950. Epub 2011 May 9.

31.

Fixation time does not affect expression of HER2/neu.

Goldsmith JD, Allred DC, Beasley MB, Eisen R, Fulton RS, Gown AM, Hammond ME.

Am J Clin Pathol. 2011 Mar;135(3):484; author reply 485. doi: 10.1309/AJCPO1ZG6FERBGZB. No abstract available.

PMID:
21350107
32.

Invasive breast cancer.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Sachdev J, Smith ML, Somlo G, Ward JH, Wolff AC, Zellars R; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Feb;9(2):136-222. No abstract available.

PMID:
21310842
33.

Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.

LaCroix AZ, Powles T, Osborne CK, Wolter K, Thompson JR, Thompson DD, Allred DC, Armstrong R, Cummings SR, Eastell R, Ensrud KE, Goss P, Lee A, Neven P, Reid DM, Curto M, Vukicevic S; PEARL Investigators.

J Natl Cancer Inst. 2010 Nov 17;102(22):1706-15. doi: 10.1093/jnci/djq415. Epub 2010 Nov 4.

PMID:
21051656
34.

Breast cancer: noninvasive and special situations.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Somlo G, Topham NS, Ward JH, Winer EP, Wolff AC.

J Natl Compr Canc Netw. 2010 Oct;8(10):1182-207. No abstract available.

PMID:
20971842
35.

Ductal carcinoma in situ: terminology, classification, and natural history.

Allred DC.

J Natl Cancer Inst Monogr. 2010;2010(41):134-8. doi: 10.1093/jncimonographs/lgq035. Review.

36.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC; American Society of Clinical Oncology; College of American Pathologists.

Arch Pathol Lab Med. 2010 Jul;134(7):e48-72. doi: 10.1043/1543-2165-134.7.e48. Review.

PMID:
20586616
37.

Postmenopausal hormone therapy: an Endocrine Society scientific statement.

Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, Burger HG, Colditz GA, Davis SR, Gambacciani M, Gower BA, Henderson VW, Jarjour WN, Karas RH, Kleerekoper M, Lobo RA, Manson JE, Marsden J, Martin KA, Martin L, Pinkerton JV, Rubinow DR, Teede H, Thiboutot DM, Utian WH; Endocrine Society.

J Clin Endocrinol Metab. 2010 Jul;95(7 Suppl 1):s1-s66. doi: 10.1210/jc.2009-2509. Epub 2010 Jun 21. Review.

PMID:
20566620
38.

PIK3CA mutations in in situ and invasive breast carcinomas.

Miron A, Varadi M, Carrasco D, Li H, Luongo L, Kim HJ, Park SY, Cho EY, Lewis G, Kehoe S, Iglehart JD, Dillon D, Allred DC, Macconaill L, Gelman R, Polyak K.

Cancer Res. 2010 Jul 15;70(14):5674-8. doi: 10.1158/0008-5472.CAN-08-2660. Epub 2010 Jun 15.

39.

Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays.

Fitzgibbons PL, Murphy DA, Hammond ME, Allred DC, Valenstein PN.

Arch Pathol Lab Med. 2010 Jun;134(6):930-5. doi: 10.1043/1543-2165-134.6.930.

PMID:
20524870
40.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC.

Arch Pathol Lab Med. 2010 Jun;134(6):907-22. doi: 10.1043/1543-2165-134.6.907. Erratum in: Arch Pathol Lab Med. 2010 Aug;134(8):1101.

41.

Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer.

Allred DC.

Mod Pathol. 2010 May;23 Suppl 2:S52-9. doi: 10.1038/modpathol.2010.55. Review.

42.

Biomarkers predicting recurrence and progression of ductal carcinoma in situ treated by lumpectomy alone.

Allred DC.

J Natl Cancer Inst. 2010 May 5;102(9):585-7. doi: 10.1093/jnci/djq118. Epub 2010 Apr 28. No abstract available.

PMID:
20427432
43.

Perceived confidence in the FAST exam before and after an educational intervention in a developing country.

Crouch AK, Dawson M, Long D, Allred D, Madsen T.

Int J Emerg Med. 2010 Feb 27;3(1):49-52. doi: 10.1007/s12245-009-0144-5.

44.

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC.

J Clin Oncol. 2010 Jun 1;28(16):2784-95. doi: 10.1200/JCO.2009.25.6529. Epub 2010 Apr 19. Review. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543.

45.

Characterization of optical constants for uranium from 10 to 47 nm.

Brimhall N, Herrick N, Allred DD, Turley RS, Ware M, Peatross J.

Appl Opt. 2010 Mar 20;49(9):1581-5. doi: 10.1364/AO.49.001581.

PMID:
20300153
46.

The Babesia bovis VESA1 virulence factor subunit 1b is encoded by the 1beta branch of the ves multigene family.

Xiao YP, Al-Khedery B, Allred DR.

Mol Biochem Parasitol. 2010 Jun;171(2):81-8. doi: 10.1016/j.molbiopara.2010.03.001. Epub 2010 Mar 10.

47.

Measured optical constants of copper from 10 nm to 35 nm.

Brimhall N, Herrick N, Allred DD, Turley RS, Ware M, Peatross J.

Opt Express. 2009 Dec 21;17(26):23873-9. doi: 10.1364/OE.17.023873.

PMID:
20052098
48.

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF; Breast Cancer Intergroup of North America.

Lancet Oncol. 2010 Jan;11(1):55-65. doi: 10.1016/S1470-2045(09)70314-6. Epub 2009 Dec 10.

49.

NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.

Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, Gown A, Hammond ME, Iglehart JD, Moench S, Pierce LJ, Ravdin P, Schnitt SJ, Wolff AC.

J Natl Compr Canc Netw. 2009 Sep;7 Suppl 6:S1-S21; quiz S22-3. Review.

PMID:
19755043
50.

Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer.

Migliaccio I, Wu MF, Gutierrez C, Malorni L, Mohsin SK, Allred DC, Hilsenbeck SG, Osborne CK, Weiss H, Lee AV.

Breast Cancer Res Treat. 2010 Oct;123(3):651-60. doi: 10.1007/s10549-009-0632-6. Epub 2009 Nov 19.

Supplemental Content

Loading ...
Support Center